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Total regression of brain metastases 
in non-small cell lung cancer patients harboring 
EGFR mutations treated with gefitinib 
without radiotherapy: two case reports
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Abstract 
Background: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. Clinical trials have reported 
its effectiveness in the treatment of brain metastases from non-small cell lung cancer by overcoming the blood–brain 
barrier. Gefitinib is generally regarded as a relatively safe agent, and several reports have described its efficacy in 
patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a poor performance 
status.
Case presentation: We herein described two patients with brain metastasis from non-small cell lung cancer who 
achieved the total regression of metastasis with the administration of gefitinib. A 70-year-old Japanese woman was 
referred to our hospital with a severe cough. Brain magnetic resonance imaging revealed a metastatic lesion in the 
left temporal lobe. The tumor was positive for an epidermal growth factor receptor L858R mutation in exon 21 using 
the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method. She was treated with 250 mg 
gefitinib per day, and, 1 month later, the primary lesion and brain metastasis had totally resolved. A 58-year-old Japa-
nese woman was referred to our hospital with nausea and headache. Brain magnetic resonance imaging revealed 
a metastatic lesion in the left cerebellar hemisphere and meningeal dissemination. The tumor was positive for the 
epidermal growth factor receptor L858R mutation in exon 21. She was treated with 250 mg gefitinib per day, and, 
3 weeks later, the primary lesion, brain metastasis, and meningeal dissemination had completely resolved.
Conclusion: We successfully treated two lung cancer patients with brain metastasis using gefitinib. Gefitinib therapy 
may be a suitable treatment for brain metastasis in lung cancer with an epidermal growth factor receptor mutation, 
particularly in elderly patients with a poor performance status.
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Background
Brain metastasis in lung cancer is a serious clinical con-
dition associated with a poor outcome. Multiple cer-
ebral lesions are associated with a poor prognosis, and 
the median overall survival from the time of diagno-
sis is approximately 3–6  months. Whole-brain radio-
therapy (WBRT) and platinum-based chemotherapy are 
the standard therapeutic choices for patients with brain 
metastases; however, the prognosis of patients with 
brain metastases is still poor. The optimal treatment for 
such patients is controversial, and the effectiveness of a 
combination of radiotherapy, chemotherapy, and epi-
dermal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKIs) remains unclear. Systemic chemotherapy is 
typically ineffective for the treatment of brain metastases 
because of the blood–brain barrier (BBB). The penetra-
tion of chemotherapeutic drugs into the central nervous 
system (CNS) is primarily limited by the BBB. Gefitinib, 
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an EGFR-TKI, was previously shown to be effective in 
the treatment of brain metastases from non-small cell 
lung cancer (NSCLC) by overcoming the BBB. An EGFR 
mutation is a predictive biomarker for a good response 
to EGFR-TKIs, even in brain metastases [1]. Gefitinib 
is generally regarded as a relatively safe agent. Several 
recent reports described its efficacy in patients with 
EGFR mutation-positive NSCLC with a poor perfor-
mance status (PS) [2].
We herein describe two cases of brain metastasis in 
lung cancer that achieved the total regression of metasta-
sis with the administration of gefitinib.
Case presentation
Case one
A 70-year-old Japanese woman without a history of 
smoking presented at our hospital with a persistent 
cough, respiratory discomfort, and a chest X-ray abnor-
mality (Fig.  1a). Lung adenocarcinoma was diagnosed 
based on the results of bronchoscopic biopsy. An EGFR 
mutation analysis identified the EGFR L858R mutation 
in exon 21 using the peptide nucleic acid (PNA)-locked 
nucleic acid (LNA) polymerase chain reaction (PCR) 
clamp method [3]. Sequential brain magnetic resonance 
imaging (MRI) revealed an enhancing nodule in the 
left temporal lobe (Fig.  1b, c). Her PS was poor (PS 3). 
Gefitinib (250  mg/day) was administered. WBRT was 
deferred because she did not exhibit any neurological 
symptoms. Her subjective symptoms improved gradu-
ally within 3 weeks of the administration of gefitinib. One 
month after the initiation of gefitinib, both the primary 
lesion and metastatic lesion were indiscernible on a fol-
low-up chest X-ray and brain MRI (Fig. 1d, e, f ). Thirty-
one months after her diagnosis, the patient died due to 
recurrence of the primary lesion. The recurrence of brain 
metastasis was not detected. We administrated gefitinib 
until 1  month before she died. She had undergone best 
supportive care for 1 month.
Fig. 1 Chest X-ray examination and T1-weighted magnetic resonance imaging (MRI) with gadolinium. a Chest X-ray examination shows consolida-
tion of the lung and pleural fluid. b and c Axial and coronal T1-weighted MRI with gadolinium. An enhanced mass lesion (red arrows) in the left 
temporal lobe was observed on admission. d The consolidation of the lung and pleural fluid was not detected 1 month after the administration of 
gefitinib. e and f Brain metastasis was not detected 1 month after the administration of gefitinib
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Case two
A 58-year-old Japanese woman without a history of 
smoking presented at our hospital with nausea, headache, 
and a chest X-ray abnormality (Fig. 2a). Lung adenocar-
cinoma was diagnosed based on the results of broncho-
scopic biopsy. An EGFR mutation analysis identified the 
EGFR L858R mutation in exon 21 using the PNA-LNA 
PCR clamp method. Sequential brain MRI showed an 
enhancing nodule in the left cerebellar hemisphere and 
meningeal dissemination (Fig.  2b). We also examined 
the cerebrospinal fluid and detected meningeal dissemi-
nation. Her PS was poor (PS 4). Gefitinib (250  mg/day) 
was subsequently administered. WBRT was deferred due 
to the absence of symptoms. Three weeks after the initia-
tion of gefitinib, both the primary and metastatic lesions 
were indiscernible on a follow-up chest X-ray and brain 
MRI (Fig.  2c, d). Nineteen months after the diagnosis, 
she died due to recurrence of the primary lesion. Neither 
the recurrence of brain metastasis nor meningeal dissem-
ination was detected. We administrated gefitinib until 
Fig. 2 Chest X-ray examination and coronal T1-weighted magnetic resonance imaging with gadolinium. a Chest X-ray examination shows consoli-
dation of the right lung. b Enhanced mass lesion (red arrow) and meningeal dissemination were revealed on admission. c The consolidation of the 
right lung was not detected 3 weeks after the administration of gefitinib. d Neither brain metastasis nor meningeal dissemination was detected 
3 weeks after the administration of gefitinib
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2 months before she died. She had undergone best sup-
portive care for 2 months.
Conclusions
NSCLC with multiple brain metastases is associated 
with a poor outcome; the overall median survival time 
of NSCLC was previously reported to be 3.5  months, 
while the one-year survival rate was 10  % [4]. There-
fore, treatment strategies for brain metastasis need to be 
commensurate with the development of systemic treat-
ments. Standard treatment options include symptomatic 
therapy with WBRT. The use of conventional chemo-
therapy for brain metastases has been limited because of 
a presumed lack of effectiveness due to poor penetration 
beyond the BBB. The ideal characteristics of compounds 
with a higher probability of crossing the BBB include a 
low molecular weight, a non-polar nature, and not being 
substrates for efflux pumps [5]. Small molecules such as 
EGFR-TKIs have the ability to cross the BBB. Cappuzzo 
and coworkers showed that EGFR-TKIs effectively pen-
etrated the BBB because of their chemical structures and 
low molecular weights [6]. Therefore, these EGFR-TKIs 
may be efficacious in the treatment of brain metastasis.
Sun and coworkers previously reported that cranial 
irradiation resulted in lower neurocognitive function in 
patients without brain metastasis than in those in the 
observation group [7]. Furthermore, dose per fraction 
reductions in prophylactic cranial irradiation have been 
suggested to avoid or reduce the late complications asso-
ciated with WBRT [8]. Since NSCLC is a relatively radio-
resistant malignancy, and WBRT induces late declines 
in cognitive function, EGFR-TKIs may be a promis-
ing option for the treatment of central nervous system 
metastasis from NSCLC.
Several recent reports described the safety and effi-
cacy of gefitinib in patients with EGFR mutation-positive 
NSCLC aged  >70  years with poor PS [2]. Gefitinib and 
erlotinib are orally active EGFR-TKIs and show signifi-
cant efficacy in patients with advanced NSCLC [9]. Since 
the hematological toxicities of EGFR-TKIs are lower than 
those of cytotoxic chemotherapy, they may be useful in the 
treatment of elderly patients and/or patients with poor PS.
In conclusion, NSCLC patients with brain metastases 
generally have poor PS. Due to its ability to reverse poor 
PS and achieve the total regression of brain metastases, 
EGFR-TKI therapy may be a suitable treatment for brain 
metastasis in lung cancer with an EGFR mutation, par-
ticularly in elderly patients with poor PS.
Consent
Written informed consent was obtained from the patients 
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ing images.
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